CMPI Report: Principles for Patient-Centered Prescription Drug Coverage


Read the Report here.


Principles for Patient-Centered Prescription Drug Coverage

Monday, September 11, 2017  
8:30am – 1:30 pm
National Press Club
Holeman Lounge
529 14th St NW
Washington, DC 20045
 
Panel One:     How PBMs Affect Access and Affordability
 
Moderator:     Peter J. Pitts, President, CMPI
Panelists:         B. Douglas Hoey, CEO, National Community Pharmacists Association
                          Nick Ferreyros, Director of Communications, Community Oncology Alliance
                          Derek Daggett, Senior Business Development Executive, SmithRx

Watch Panel One highlights here.

Keynote Speaker: A. Mark Fendrick, M.D., Director, Center for Value Based Insurance Design, University of Michigan
Introduction by Robert M. Goldberg, CMPI

Watch Dr. A. Mark Fendrick's Keynote Remarks here.

Panel Two:     Principles for PBM Reform and Patient-Centered Prescription Drug Benefits
 
Moderator:   Robert M. Goldberg, PhD, Vice President, CMPI
Panelists:       Shawn Lovering, President, RxTE
                        Susan Pilch, Vice President, Policy & Regulatory Affairs, NCPA
                        A. Mark Fendrick, M.D., University of Michigan
                        Burt Zweigenhaft, Managing Partner, Upstream Partners
 
Watch Panel Two highlights here.
Sign Up for Our Email Newsletter

RECENT NEWS

Streamline drug approval process

Streamline drug approval process

When Americans don't fill their prescriptions, their illnesses worsen, which drives up healthcare spending....  Read more

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

A key problem with Mr. Azar’s transparency effort is that it doesn’t provide consumers with any context or insights into ...  Read more

Safe Harbor Sunshine And Flat Fees: Vital Steps Towards Smarter Drug Spending

Safe Harbor Sunshine And Flat Fees: Vital Steps Towards Smarter Drug Spending

The current system encourages payers to favor medicines that carry higher rebates than lower list-priced drugs....  Read more

DRUGWONKS BLOG